EGFR and non-small cell lung carcinoma: Treatment with EGFR-tyrosine kinase inhibitors (TKIs) in NSCLC patients harboring sensitizing EGFR mutations, is associated with significant survival benefits and better quality of life compared with conventional chemotherapy [5,6,8,9].